**TOP STOCK PICKS

[Robertscott]

$TXTM Cannabis Biosciences is focused on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing. Using proprietary processing and extraction technology developed by Plandaí Biotechnology, Inc, the company intends to commence investigations in conjunction with independent researchers to establish whether it can produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The hypothesis is that the resultant extract will have the superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive. Several third-party investigations have shown that the precursor acid forms THC-A and THC-B in live cannabis leaf are inherently non-psychoactive and that the process of drying and heating the leaf metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The Company’s investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.

http://www.protextm.co/